

REMARKS


Upon entry of the amendment, claims 59, 66, 78, 84, 86-87 and 89 will be pending in this application. Claims 60-64, 69, 79-83, 85, 88 and 90 have been cancelled. Applicant reserve the right to pursue all of the non-elected subject matter, including all cancelled claims, in a divisional application. Applicants reserve the right to pursue any cancelled, elected subject matter in a continuing application. Support for the amendments made herein can be found at least at page 2, lines 4-6. No new matter has been added.

In response to the Restriction Requirement mailed September 18, 2007, Applicants elect Group 2, claims 59-64, 66, 69 and 78-90, as drawn to a composition comprising an agent for suppressing an immune response and a gastrin/CCK receptor ligand; and a method of treating a diabetic subject comprising administering the same. Further, Applicants elect rapamycin as the agent and gastrin17Leu15 as the gastrin/CCK receptor ligand. Applicants have not elected an EGF receptor ligand as the claims have been amended so that they are no longer directed to an EGF receptor ligand. All of the pending claims read on the elected species.

Applicants also submit a Petition for a Five Month Extension of Time and the appropriate fee. With the Petition, a Response is due on or before March 18, 2008. Applicants believe no additional fees are due, however, please charge any payments or credit any overpayments of the same to Deposit Account No. 50-0311, reference 24492-010NATL. Should any questions or issues arise concerning the application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: March 12, 2008

Respectfully submitted,

 Reg No. 58,032

Ivor R. Elrifi, Reg. No. 39,529

for: David E. Johnson, Reg. No. 41,874
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000